Clinical trial · no report yet · Phase 1
NCT04897321
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- NCT04897321 ↗
- Recruiting
- St. Jude Children's Research Hospital
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 14 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
- Interventions
- Fludarabine; Cyclophosphamide; MESNA; B7-H3 CAR T cells
- Arms
- Treatment Phase · Other
- Enrollment
- 48 (estimated)
- Primary outcomes
- Safety of B7-H3-CAR T cells
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 6, 2022
- Primary completion
- Mar 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04897321 · updated May 19, 2026